Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. BFRI
stocks logo

BFRI

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
15.54M
+23.72%
0.100
-143.1%
9.10M
+5.96%
-0.180
-64.59%
10.00M
+10.74%
-0.120
-78.79%
Estimates Revision
The market is revising Downward the revenue expectations for Biofrontera Inc. (BFRI) for FY2025, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -1.88%.
Revenue Estimates for FY2025
Revise Downward
down Image
-1.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.03%
In Past 3 Month
Stock Price
Go Down
down Image
-1.88%
In Past 3 Month
Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Analyst Rating
Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.828
sliders
Low
3.00
Averages
6.00
High
9.00
Current: 0.828
sliders
Low
3.00
Averages
6.00
High
9.00
Roth Capital
Buy
upgrade
$8 -> $10
2025-06-30
Reason
Roth Capital
Price Target
$8 -> $10
2025-06-30
upgrade
Buy
Reason
Roth Capital raised the firm's price target on Biofrontera Inc. to $10 from $8 and keeps a Buy rating on the shares. The firm notes Biofrontera Inc. acquired full U.S. Ameluz and RhodoLED rights from former parent company Biofrontera AG, which, when combined with the $11M investment from existing institutional investors, funds Biofrontera Inc. to profitability.
Benchmark
Bruce Jackson
Buy
downgrade
$7
2025-05-19
Reason
Benchmark
Bruce Jackson
Price Target
$7
2025-05-19
downgrade
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Biofrontera Inc (BFRI.O) is -1.97, compared to its 5-year average forward P/E of -12.72. For a more detailed relative valuation and DCF analysis to assess Biofrontera Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-12.72
Current PE
-1.97
Overvalued PE
33.30
Undervalued PE
-58.73

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.10
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.27
Undervalued EV/EBITDA
-0.48

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.58
Current PS
0.00
Overvalued PS
1.30
Undervalued PS
-0.14
Intellectia AI SwingMax
Intellectia AI SwingMax

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
AI Stock Picker
AI Stock Picker

BFRI News & Events

Events Timeline

(ET)
2025-12-04
09:20:00
Biofrontera Completes Final Patient Visit in Ameluz Phase 1 Study
select
2025-12-02 (ET)
2025-12-02
08:50:00
Biofrontera Submits sNDA for Ameluz-PDT Treatment of sBCC
select
2025-11-13 (ET)
2025-11-13
08:16:07
Biofrontera Announces Q3 Earnings Per Share of 62 Cents Compared to a Loss of 98 Cents Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
12-04Newsfilter
PinnedBiofrontera Completes Phase 1 Study of Ameluz®; Plans FDA Submission for 2026
  • Research Milestone: Biofrontera has completed its Phase 1 pharmacokinetic study of Ameluz®, involving 17 patients applying three tubes over a treatment area of 240 cm², marking a significant step towards a planned FDA submission in summer 2026.
  • Market Demand: The study results will be combined with data from a recently completed Phase 3 trial to support a supplemental New Drug Application (sNDA) to the FDA, aiming to expand Ameluz®'s indications to all peripheral body areas, addressing a critical need in dermatology.
  • Patient Benefits: If approved, this indication expansion will provide significant treatment options for patients, and Biofrontera anticipates that it will greatly enhance its leadership position in the photodynamic therapy market.
  • Industry Impact: With approximately 58 million people affected by actinic keratosis in the U.S. as of 2020, Ameluz® could become a key drug for treating this common skin lesion if approved, further driving the company's business growth.
[object Object]
Preview
9.5
11-13Newsfilter
Biofrontera Inc. Announces Financial Results for Q3 2025 and Offers Business Update

  • Financial Performance: Biofrontera Inc. reported stable revenues of $24.6 million for the first nine months of 2025, slightly down from $24.8 million in 2024, with a notable decline in Q3 revenues to $7.0 million due to advanced purchases ahead of a price increase.

  • Operational Developments: The company completed the acquisition of U.S. rights for Ameluz and RhodoLED assets, which is expected to enhance gross margins and profitability, and announced the divestiture of its Xepi antibiotic cream for up to $10 million in total payments.

  • Clinical Trials Update: Biofrontera announced the completion of the active treatment phase for its Phase 3 clinical trial of Ameluz for actinic keratoses and the conclusion of participation in a Phase 2b trial for acne vulgaris.

  • Future Outlook: CEO Hermann Luebbert expressed confidence in achieving full-year sales objectives, anticipating substantial growth in Q4, supported by a revamped sales strategy and increasing demand for Ameluz-PDT treatments.

[object Object]
Preview
7.5
11-07Benzinga
EXCLUSIVE: Pelthos Acquires Antimicrobial Drug Rights and Raises $18 Million for Commercial Launch Support

  • Acquisition of Xepi: Pelthos Therapeutics Inc. has acquired U.S. commercialization rights to Xepi (ozenoxacin) Cream from Biofrontera Inc. and Ferrer Internacional S.A. for a total of $4.2 million, with plans to relaunch the product in late 2026.

  • Product Details: Xepi is a topical antimicrobial treatment for impetigo, a contagious skin infection affecting around 3 million people in the U.S. annually, particularly children aged 2 to 5.

  • Funding for Commercialization: Pelthos has secured $18 million in private convertible notes financing to support the acquisition and relaunch of Xepi, as well as to accelerate the commercialization of another product, Zelsuvmi.

  • Market Response: Following the acquisition announcement, Pelthos Therapeutics shares remained stable at $37.42 during premarket trading, indicating limited movement in the stock price.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Biofrontera Inc (BFRI) stock price today?

The current price of BFRI is 0.8284 USD — it has increased 4.41 % in the last trading day.

arrow icon

What is Biofrontera Inc (BFRI)'s business?

Biofrontera Inc. is a biopharmaceutical company. The Company specializes in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT). The PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses of mild-to-moderate severity on the face and scalp. The Company’s primary licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (the RhodoLED Lamps), are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions. The Company commercializes the drug-device combination Ameluz with the RhodoLED lamp series for PDT of AK, pre-cancerous skin lesions which may progress to invasive skin cancers. Its belixos ACTIVE CARE is a skin-soothing care foam for irritated and itchy skin, which can be used as basic care for atopic dermatitis and psoriasis as well as for soothing intensive care for everyday skin problems.

arrow icon

What is the price predicton of BFRI Stock?

Wall Street analysts forecast BFRI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BFRI is 6.00 USD with a low forecast of 3.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Biofrontera Inc (BFRI)'s revenue for the last quarter?

Biofrontera Inc revenue for the last quarter amounts to 6.99M USD, decreased -22.46 % YoY.

arrow icon

What is Biofrontera Inc (BFRI)'s earnings per share (EPS) for the last quarter?

Biofrontera Inc. EPS for the last quarter amounts to -0.62 USD, decreased -36.73 % YoY.

arrow icon

What changes have occurred in the market's expectations for Biofrontera Inc (BFRI)'s fundamentals?

The market is revising Downward the revenue expectations for Biofrontera Inc. (BFRI) for FY2025, with the revenue forecasts being adjusted by -1.23% over the past three months. During the same period, the stock price has changed by -1.88%.
arrow icon

How many employees does Biofrontera Inc (BFRI). have?

Biofrontera Inc (BFRI) has 92 emplpoyees as of December 05 2025.

arrow icon

What is Biofrontera Inc (BFRI) market cap?

Today BFRI has the market capitalization of 9.65M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free